Merrimack Pharmaceuticals, Inc. (MACK) has an overall financial health rating of C+ with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2024-05-17.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2024-05-17 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-16 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-15 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-14 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-13 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-08 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-07 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-03 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-02 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
